Climb Bio, Inc. (CLYM)
NASDAQ: CLYM · Real-Time Price · USD
7.18
-0.21 (-2.84%)
Mar 6, 2026, 4:00 PM EST - Market closed
Climb Bio Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 21.17 | 15.39 | 9.89 | 18.92 | 12.35 | |
| Research & Development | 46.71 | 11.61 | 11.58 | 26.21 | 23.32 | |
| Operating Expenses | 67.88 | 27 | 21.47 | 45.14 | 35.67 | |
| Operating Income | -67.88 | -27 | -21.47 | -45.14 | -35.67 | |
| Interest & Investment Income | 8.32 | 8.13 | 2.29 | 1.2 | 0.45 | |
| Currency Exchange Gain (Loss) | -0.29 | -0.01 | 0.54 | -1.48 | -0.17 | |
| Other Non Operating Income (Expenses) | - | - | - | - | -11.72 | |
| EBT Excluding Unusual Items | -59.85 | -18.88 | -18.64 | -45.42 | -47.11 | |
| Merger & Restructuring Charges | - | -3.36 | -18.81 | - | - | |
| Gain (Loss) on Sale of Investments | - | - | 2.33 | 0.18 | -0.37 | |
| Pretax Income | -59.85 | -73.9 | -35.12 | -45.24 | -47.48 | |
| Net Income | -59.85 | -73.9 | -35.12 | -45.24 | -47.48 | |
| Preferred Dividends & Other Adjustments | - | - | - | - | 4.55 | |
| Net Income to Common | -59.85 | -73.9 | -35.12 | -45.24 | -52.03 | |
| Shares Outstanding (Basic) | 67 | 48 | 27 | 26 | 12 | |
| Shares Outstanding (Diluted) | 68 | 48 | 27 | 26 | 12 | |
| Shares Change (YoY) | 40.80% | 78.47% | 2.57% | 114.60% | 460.40% | |
| EPS (Basic) | -0.90 | -1.53 | -1.30 | -1.72 | -4.24 | |
| EPS (Diluted) | -0.90 | -1.53 | -1.30 | -1.72 | -4.24 | |
| Free Cash Flow | -54.54 | -15.56 | -20.6 | -37.37 | -36.07 | |
| Free Cash Flow Per Share | -0.80 | -0.32 | -0.76 | -1.42 | -2.94 | |
| EBITDA | -67.79 | - | - | - | - | |
| D&A For EBITDA | 0.1 | - | - | - | - | |
| EBIT | -67.88 | -27 | -21.47 | -45.14 | -35.67 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.